ArticleDiscover oncology2025
Mechanistic evaluation of hyperoside against non-small cell lung cancer: a combined approach of network pharmacology and in vitro experimental validation.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHyperoside (Hyp) exerts considerable inhibitory effects on non-small-cell lung cancer (NSCLC) cells. However, the underlying molecular mechanisms have not been fully elucidated. We aimed to explore the molecular mechanisms of Hyp in the treatment of NSCLC using a combination of network pharmacology and in vitro experiments.
methodsActive targets of Hyp and NSCLC-related targets were identified using public databases. The therapeutic targets were predicted based on the intersection of drug and disease targets. A protein-protein interaction (PPI) network was constructed using STRING and Cytoscape, and key network modules and targets were identified through network topology analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using DAVID. Molecular docking between Hyp and therapeutic targets was performed using AutoDock Vina software. These results were further verified by in vitro experiments of A549 cell lines, including the CCK-8 assay, EdU staining, flow cytometry and western blotting.
resultsA total of 30 therapeutic targets of Hyp against NSCLC were identified. Analysis of the PPI network revealed a key network module and five key targets: MMP9, CASP3, MAPK1, ESR1, and EGFR. These targets were related to cell proliferation and migration, apoptosis, and oxidative stress and may play a role through the FoxO, MAPK, Rap1, Ras, and PI3K-Akt signaling pathways. Molecular docking results showed a strong binding affinity between Hyp and most therapeutic targets. Further experiments confirmed that Hyp inhibited proliferation and induced apoptosis of A549 cells by regulating the EGFR/ERK/FOXO1 signaling pathway.
conclusionsHyp may be a promising drug for treating NSCLC (especially lung adenocarcinoma), and its therapeutic mechanisms is closely related to the regulation of EGFR/ERK/FOXO1 pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.